TOPAZ: Single Arm, Open Label Phase 1b/2 Study of Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT04512261

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-28T10:38:35.544811+00:00

Published At

2022-07-01T00:00:00+00:00

Record Updated At

2022-07-01

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Breast Cancer", "Brain Metastases", "HER2-positive Breast Cancer", "CNS Disease"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2022-07-01"

protocolSection.identificationModule.nctId

"NCT04512261"

protocolSection.identificationModule.officialTitle

"TOPAZ: Single Arm, Open Label Phase 1b/2 Study of Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases"

protocolSection.statusModule.overallStatus

"WITHDRAWN"

protocolSection.designModule.phases

["PHASE1", "PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

""

Study condition terms

• Breast Cancer (protocolSection.conditionsModule.conditions)
• Brain Metastases (protocolSection.conditionsModule.conditions)
• HER2-positive Breast Cancer (protocolSection.conditionsModule.conditions)
• CNS Disease (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.